Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-28T20:26:41.997Z Has data issue: false hasContentIssue false

Author's Reply

Published online by Cambridge University Press:  02 January 2018

M.-F. Poirier*
Affiliation:
Centre Hospitalier Sainte-Anne, I, rue Cabanis, 75674 Paris Cedex 14, France
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © 2000 The Royal College of Psychiatrists 

We do not consider that our study was “inherently biased in favour of venlafaxine” for three main reasons:

  1. (a) The proportion of two-thirds of patients included in each group who were previously resistant to treatment with an SSRI is a realistic picture of what is observed in everyday practice, since the prescription of an SSRI is now the predominant one in any type of depression.

  2. (b) Two-thirds of the patients included in the venlafaxine (a serotonin and noradrenaline reuptake inhibitor) group were previously resistant to tricyclic antidepressant drugs, which also act on noradrenaline and serotonin. The bias in favour of venlafaxine is in the same proportion as the bias in favour of paroxetine.

  3. (c) There is no clear evidence that a patient resistant to an SSRI must not be switched to another SSRI. Not all SSRIs are the same, and the consistent pharmacological differences between these drugs authorise our point of view for such a switch.

What is more, Dr Daniels' opinion, that when a patient is resistant to an SSRI subsequent treatment with paroxetine (another SSRI) should be avoided, is likely to be incorrect as in our study, a significant number of patients previously resistant to an SSRI afterwards responded to treatment with paroxetine.

The fact that no significant differences were observed between venlafaxine and paroxetine with respect to the mean HAM-D change, both in the observed-case and in the LOCF analyses, was fully recognised in our report. The main differences we reported between the two drugs was in remission rate - an important criterion for prediction of future outcome.

Finally, regarding the dosages of the drugs used, at the time the study protocol was designed, paroxetine dosage (including dose titration) was not very clear in terms of regulatory recommendations (in France at least) and it was not possible to recommend a dosage of paroxetine as high as 40 mg/day. This can be seen as too low now, in the light of subsequent research on the dose-response relationship for paroxetine.

Submit a response

eLetters

No eLetters have been published for this article.